On June 26, 2021, Shanghai: Sanyou Biopharmaceutical (Shanghai) Co., Ltd. (hereafter referred to as "Sanyou Bio" or "the Company"), a leading company in innovative antibody drug discovery, announced the closing of series B financing. This financing round was co-led by LH Ventures and Montesy Investment, and followed by Grand Mount Capital and Seeking Capital (an existing investor). After this round of financing, Zhiyin Lan, venture partner of LH Ventures, will join the Board of Directors of Sanyou Bio. Previously, Sanyou Bio obtained joint series-A funding from Haier Biomedical and Shanghai Liferiver Bio-Tech in May 2020.
Established in 2015, Sanyou Bio focuses on R&D of innovative antibody drugs. The Company¡¯s vision is to improve quality of life with innovative antibody drugs, and their mission is to empower the industry to develop any innovative antibody drug. Sanyou Bio have been continuously building a world-leading high-throughput integrated R&D platform for innovative antibody drugs, collecting technical resources to establish the largest antibody library in the world. While providing leading services, Sanyou Bio have made every effort to collaborate with their partners to develop innovative antibody drugs to meet the patients¡¯ need.
After 6 years of persistent endeavor, Sanyou Bio has established a state-of-the-art integrated R&D platform for innovative antibody drug discovery, provided hundreds of unique R&D solutions and technical services for innovative antibody drug discovery projects to more than 150 pharmaceutical companies and drug development institutions around the world, and carried out more than 10 collaborative R&D projects with more than 10 partners.
Dr. David (Guojun) Lang, CEO of Sanyou Bio, stated, "we are very grateful to our previous and new investors for their recognition and support. We will make the best use of this funding round to expand our R&D and service teams, expedite the launching process of a number of super-trillion antibody libraries, and build a world-leading modular, automated, and integrated innovative antibody drug integrated R&D service platform to overcome the difficulty of finding top-notch candidate molecules of innovative antibody drugs and clear the path from a target selection to IND application. We hope that all companies and individuals aspired to R&D of innovative antibody drugs can leverage fully with Sanyou Bio s open platform to achieve their pursuit of new drug development."
About Sanyou Biopharmaceuticals
Sanyou Biopharmaceuticals Co., Ltd. is a leading international biological high-tech enterprise focusing on R&D and services of innovative antibody drugs.
The company is committed to establishing a leading high-quality, high-throughput, and integrated R&D and value transformation platform for innovative antibody drugs internationally, constructing a business ecosystem involving therapy, R&D, and diagnostic products and services, and cooperating with global biopharmaceutical, diagnostic, and drug R&D companies to make a new progress in the diagnosis and treatment of human diseases.
Since its establishment 6 years ago, Sanyou Bio has maintained rapid development. As of May 2021, the company has more than 160 members in a professional team, of which the proportion of doctors and masters is more than 70%. The team has full experience in innovative drug development and industrialization. Sanyou Bio has established an integrated innovative antibody drug R&D laboratory of several thousand square meters with advanced facilities in "Shanghai Caohejing Hi-Tech Park". There are 10 major functional modules and more than 40 core technological platforms which are characterized by a series of sub-Trillion phage display antibody libraries, covering innovative antibody drug discovery, antibody engineering,in vitro and in vivo efficacy screening, antibody drug developability analysis, construction of cell lines for production, and manufacturing process development, etc.
The company is continuing to launch new technologies, new products, new services, and new scenarios of "the best quality, the fastest speed, and the highest cost performance". Friendly business cooperation relations have been established by the company with more than 150 pharmaceutical companies, drug R&D institutions, and diagnostic reagent and product development companies worldwide.
Excellence and innovation, pursuit of dreams, striving and envolving, for the benefit of patients! Sanyou Bio looks forward to jointly building a long-term collaborative growth ecosystem and a healthy society with our clients and partners.
